
    
      This is a 6 month, multicenter, randomized, open label, parallel group, safety study of
      ciclesonide nasal aerosol and ciclesonide aqueous nasal spray administered once daily to male
      and female subjects 12 years and older diagnosed with PAR. The objectives of this study are
      to evaluate the nasal and ocular safety of once daily dosing with ciclesonide nasal aerosol
      (Zetonna) 74 mcg and ciclesonide aqueous nasal spray (Omnaris) 200 mcg in subjects 12 years
      and older with PAR.
    
  